Brief: CytRx's aldoxorubicin continues to show no clinically significant cardiac toxicity
27/05/2015 14:02
May 27 (Reuters) - CytRx Corp CYTR.O : * To present aldoxorubicin clinical data at the 2015 asco annual meeting * Says aldoxorubicin continues to demonstrate no clinically significant cardiac toxicity * Source text for Eikon ID:nPn1whsnG * Further company coverage CYTR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C